EFFICACY AND TOLERABILITY OF SUBCUTANEOUS V/S ORAL METHOTREXATE IN THE MANAGEMENT OF MODERATE TO SEVERE PSORIASIS AND PALMOPLANTAR PSORIASIS - A HOSPITAL BASED PROSPECTIVE RANDOMIZED CONTROLLED COMPARATIVE STUDY

DrPooja0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

研究概览

暂无简介。

•a) diagnosed to be suffering from Moderate to Severe Psoriasis and palmoplantar psoriasis or palmoplantar psoriasis clinically in
•DERMATOLOGY OPD of a tertiary care centre in Karad
•b)Have completed 18 years of age.
•c)Have not taken any treatment, two months prior to the inclusion in study.

•1.Hemoglobin < 8 gm/dl ,Total leukocyte count < 3500/ mm3, Platelet count < 100,000/mm3
•2.Elevation of hepatic enzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) to more than twice the upper limit of normal or any deranged liver function tests.
•3.Hepatitis, active or recurrent, cirrhosis or excessive current alcohol intake.
•4.Use of other hepatotoxic drugs by the patient
•5.Positive hepatitis B, hepatitis C or HIV serology
•6.Pulmonary or extra-pulmonary active tuberculosis
•7.Deranged renal function test.
•8.Pregnancy or lactation or if patient is planning to conceive during the treatment period.
•9.Patient on other immunosuppressive drugs
•10.Recent live vaccination
•11.Unreliable patient
•12.Patients unwilling for monthly follow-ups.
•13.Patient with known hypersensitivity to drug.
•14.Patient with unrealistic expectation

发起方

DrPooja